GLP-1 Inspired Formulation Strategies and Regulation Realities

The beauty industry has always had an extraordinary ability to respond to change at speed. Right now, one of the most significant biological shifts happening at scale is being driven not by a new ingredient trend, but by a prescription medication that was never designed with skin in mind.

GLP-1 receptor agonists are reshaping bodies at a rate science did not fully anticipate and the skin science conversation that needs to follow has, frankly, not kept pace with the marketing.

Glucagon-like peptide-1 (GLP-1) as its name suggests, is both a peptide and gut hormone linked to appetite control and weight loss. It was first discovered in the 1970s, with its role in insulin regulation formally identified in 1987.

For decades, its broader physiological significance remained relatively underexplored. That changed in the early 2000s and by 2005, GLP-1 receptor agonists began entering medicinal use specifically for treating type II diabetes.

GLP-1 is secreted by L-cells in our small intestine in response to eating. Its role is to signal the pancreas to release insulin and slow down the rate at which the stomach empties food into the small intestine, it then sends signals of feeling full to the brain. The result is reduced appetite and a more controlled glucose response following a meal.

However, the limitation of GLP-1 produced naturally is that it is degraded by an enzyme called DPP-4 within minutes of release, meaning its window of action is very brief.

Whereas, GLP-1 receptor agonists are prescription injectables developed to resist that degradation, mimicking the hormone's action on appetite, satiety and glucose control with a sustained, clinically meaningful duration.

This mechanism is why these medications produce the weight loss outcomes that clinical trials have demonstrated and it is also why they are now the fastest-growing pharmaceutical category globally.

Large randomised, double-blind, placebo-controlled trials demonstrated significant reductions in body mass and adiposity in patients with obesity and type II diabetes (Jastreboff et al. 2022).

What those trials primarily tested was weight loss efficacy and metabolic markers, not skin ageing, facial volume or long-term connective tissue outcomes. That gap in the evidence matters and we will return to it.

What followed has been one of the most unprecedented adoption curves in pharmaceutical history. Globally, the GLP-1 receptor agonist market is projected to reach USD 156.71 billion by 2030, at a compound annual growth rate of 17.46% (Grand View Research, 2024).

NielsenIQ data has shown that GLP-1 users spend at least 1.3 times more on health and beauty than non-users. Goldman Sachs, in March 2025, estimated the GLP-1 beauty economy could represent USD 3–5 billion in incremental US consumer spending annually by 2028.

This is a demographically significant, high-engagement, high-spend consumer cohort arriving at beauty with very specific and legitimate skin concerns.

This is where science becomes both important but frequently misrepresented and where the industry has a real responsibility to get this right.

Weight loss of any kind, when it occurs rapidly and at significant magnitude, changes the structural landscape of the face and body. Facial fat exists in distinct compartments, superficial and deep, that function not just as volume but as active biological tissue.

When these fat pads reduce, the structural support they provide to overlying skin is diminished and the result is what has been named as ‘Ozempic face’. It visibly appears as hollowing in the midface and temples, deepening of nasolabial and marionette folds with an impression of premature ageing.

A 2025 published review describes this exaggerated volume loss associated with GLP-driven weight change but the mechanism goes considerably deeper than geometry.

A peer-reviewed paper highlighted a more complex pathway. GLP-1 receptor agonists can act directly on fibroblasts and adipose-derived stem cells (ADSCs) which are a type of mesenchymal stem cell found in fat tissue for repair and regeneration, both of which carry GLP-1 receptors on their surface (Martin, E. et al. 2025).

Stimulation of those receptors reduces the ability of ADSCs to produce protective cytokines (normally shield the skin from damage) which in turn promotes the production of reactive oxygen species and creates oxidative damage at the fibroblast level.

Additionally, GLP-1 receptor agonists reduce glucose uptake by ADSCs, leading to reduced ATP production and cellular apoptosis. Critically, stimulation of GLP-1 receptors on ADSCs also reduces the production of oestrogens from dermal white adipose tissue and oestrogen is a key driver of fibroblast activity and collagen synthesis.

The downstream effect is a measurable reduction in the skin's own structural production capacity (Ridha et al. 2025). To put it plainly, this is not just a volume story.

There is emerging evidence of a biological mechanism affecting collagen and elastin production at the dermis, operating independently of how much weight is lost. The skin's internal infrastructure is being altered through a signalling pathway, not just structurally deflated from the outside in.

Long-term, real-world data is still emerging. This gap matters, particularly as clinicians have raised concerns around lean mass loss and muscle preservation during prolonged GLP-1 use.

Nutrition is also a factor being taken into consideration. GLP-1 medications significantly reduce caloric intake by an estimated 15–20% (ING Think, 2025). When that reduction is not carefully managed with adequate protein, vitamins and minerals, the downstream consequence is compromised skin barrier integrity, reduced collagen precursor availability and clinically observable skin dehydration.

This is the side effect that is both genuinely common and the one that topical formulation is best positioned to address.

Another category gaining attention is GLP-1-associated hair loss, likely reflecting the physiological stress and nutritional disruption that can accompany rapid weight change - a topic I explored separately in Haircare Reformulated.

For formulators, that creates a realistic and commercially credible opportunity around scalp comfort, fibre condition and the appearance of healthier-looking hair, rather than any medical claims.

Skincare cannot restore lost fat pads, reach the dermal white adipose tissue layer or restore the paracrine signalling between adipocytes and fibroblasts that has been disrupted.

Sub-dermal structural changes in GLP-1 consumers sit categorically outside the scope of skincare intervention and claiming otherwise would, across EU, UK and US frameworks, cross into drug claim territory.

Under EU Cosmetic Regulation (EC) No 1223/2009, skincare may not claim to modify physiological function; UK regulation aligns with the same principle while FDA classification turns on intended use. This is not a grey area, it is a regulatory exposure.

What topical formulation can credibly do is address epidermal and superficial dermal effects. As caloric intake reduces, skin barrier lipid synthesis is compromised, TEWL increases and the surface presents as dullness, tightness and exaggerated fine lines.

Actives with an evidence base in collagen signalling and texture improvement can sit within firmness-supportive positioning, provided framing is mechanistically defensible and underpinned by third party clinical data.

The framing for the GLP-1 skincare category must be credible, defensible and serve the consumer well. They also happen to reflect what the products can actually deliver.

There is a genuine, significant and commercially meaningful role for formulators and innovators in this space. The GLP-1 consumer is health-engaged, scientifically curious and an intentional buyer.

RealSelf reported GLP-1-related content traffic up 2,080% year-on-year; which means their expectations of what skincare can do are often shaped by clinical procedure conversations. McKinsey found GLP-1 use is reshaping the aesthetics customer base, with many first-time patients presenting specifically for volume loss and laxity.

The formulator's role here is to meet that consumer with transparency, rigorous science and products that genuinely help with the concerns that are topically addressable.

That means barrier and hydration first, sensory elegance matters enormously because a dehydrated, sensitised skin in rapid change is not tolerant of heavy fragrances, high-active overloading or unnecessarily complexity.

Extend the thinking beyond the face, too. Body skin crepeyness and laxity on the arms, abdomen and décolleté is often more visually prominent than facial change and consistently underserved by current product ranges.

The scalp and hair loss conversation deserves its own formulation brief. GLP-1 associated hair shedding is one of the more commonly reported side effects among users. It reflects the physiological stress, caloric restriction and nutritional disruption that accompany rapid weight change.

Telogen effluvium, the stress-induced hair cycle disruption that pushes follicles prematurely into the resting phase, is a well-understood phenomenon in the context of significant weight loss.

The credible opportunity sits in scalp comfort formulations that address the sensitivity accompanying the condition, fibre-focused products that improve the cosmetic appearance of thinning hair and ingestible support targeting the nutritional gaps that underpin the shedding.

This is a category where the science is clear, the consumer need is real and the formulation response is both feasible and defensible.

For formulators in the ingestible space, nutricosmetics represent the most compelling opportunity to emerge from the GLP-1 wave. The fundamental challenge for these users is not simply weight loss, it is compromised nutritional intake.

Appetite suppression of 15–20% means users frequently fall short of the protein, vitamins and minerals that skin, hair and muscle tissue depend on. The visible consequences of sagging, thinning, dullness and hair shedding are the downstream signal of systemic nutritional depletion and that is precisely where ingestible formulation science has a scientifically coherent and clinically meaningful role.

Supplements with low molecular weight collagen and amino acid formats are among the more evidence-supported strategies for supporting skin elasticity and dermal quality from within. Vitamins A, C and E, along with key minerals frequently depleted in calorie-restricted states, each play a documented role in barrier function, antioxidant defence and collagen synthesis.

A well-formulated nutricosmetic addresses these deficiencies systematically, not as a multivitamin but as a formulation built around the specific gaps that GLP-1-driven appetite suppression creates. High-protein formulations supporting lean mass retention sit at the intersection of weight management and beauty-from-within in a commercially differentiated way. While oral ceramides and antioxidant-rich ingestibles complement topical intervention at the barrier level.

What nutricosmetics must not do is overreach, the same regulatory principle that governs topical claims applies equally here, language must be functional, evidence-led and within the scope of what these products can genuinely deliver.

There is also a compelling formulation opportunity where skincare is positioned intelligently as part of a wider support routine, one that works alongside, rather than in competition with the other interventions a GLP-1 user may be navigating.

Facial massage tools and manual techniques may support superficial microcirculation, help reduce the appearance of puffiness and deliver a temporarily fresher, more refreshed-looking result.

Relevant for a consumer experiencing rapid facial change but these are supportive measures, not structural correction. They do not restore lost fat compartments or reverse deeper tissue-level changes and the formulation that accompanies them should consider these regulatory limitations.

Where concerns move beyond surface dehydration and into visible crepiness, laxity or meaningful loss of skin quality, the conversation often shifts into clinic. Skin boosters are designed to improve hydration and skin smoothness within the dermis.

In aesthetic medicine, structural concerns are typically addressed through volume restoration, energy-based tightening, biostimulatory approaches and tissue repositioning.

Skincare plays a genuine and valuable role in managing dehydration, barrier disruption and surface texture but it cannot restore lost adipose tissue or meaningfully replace deep-dermal collagen and elastin experienced by GLP-1 consumers. The opportunity is not to blur those boundaries but to build routines intelligently around them.

A well-designed formulation does not need to be overclaimed to be useful, in the right context positioned alongside a protocol-led routine may deliver meaningful value at every step of the consumer journey. 

Beauty is no longer a standalone category, it is part of a broader wellness ecosystem.

GLP-1 therapies represent one of the most significant inflection points the beauty industry has seen in decades, not because they directly alter skin biology but because they accelerate bodily change and are shifting consumer expectations.

GLP-1 hasn’t diminished the role of skincare, it has raised the bar for what credible, science-led beauty can deliver.

The science here is still developing, longitudinal studies in GLP-1 users, better comparisons with other forms of weight loss and more rigorous work on dermal architecture, adipose signalling and fibroblast behaviour will be essential before the category can move with full confidence beyond what is currently observable.

For now, responding intelligently to what is visible, measurable and topically or nutritionally addressable is not a limitation, for a scientifically credible industry that is exactly where the opportunity lives.

References

Bissett, D.L., Oblong, J.E. and Berge, C.A. (2005) ‘Niacinamide: A B vitamin that improves aging facial skin appearance’, Dermatologic Surgery, 31(7 Pt 2), pp. 860–865.

Boo, Y.C. (2021) ‘Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation’, Antioxidants, 10(8).

Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Nielsen, S., Lou, J., Kushner, R.F. and SURMOUNT-1 Investigators (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), pp.205-216.

Boo, Y.C. (2022) ‘Ascorbic acid (Vitamin C) as a cosmeceutical to increase dermal collagen for skin antiaging purposes’, Antioxidants, 11(8).

Daneshgaran, G. et al. (2025) ‘“Ozempic Face” in plastic surgery: A systematic review of the literature on GLP-1 receptor agonist-mediated weight loss and analysis of public perceptions’, Plastic and Reconstructive Surgery – Global Open.

Enescu, C.D. et al. (2022) ‘A review of topical vitamin C derivatives and their efficacy’, Journal of Cosmetic Dermatology.

Gehring, W. (2004) ‘Nicotinic acid/niacinamide and the skin’, Journal of Cosmetic Dermatology, 3(2), pp. 88–93.

Huang, H.Y. et al. (2025) ‘Tretinoin for photodamaged facial skin: systematic review’.

KFF (2025) ‘Poll: 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes or another condition, even as half say the drugs are difficult to afford’, 14 November.

Kantar (2025) ‘GLP-1 agonists: the next big disruptor in society’, 12 August.

MHRA/GOV.UK (2021) Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain.

Paschou, I.A. et al. (2025) ‘GLP-1RA and the possible skin aging’, Endocrine.

Pullar, J.M., Carr, A.C. and Vissers, M.C.M. (2017) ‘The roles of vitamin C in skin health’, Nutrients, 9(8).

Schild, J. et al. (2024) ‘The role of ceramides in skin barrier function and inflammatory skin diseases’.

Sitohang, I.B.S. et al. (2022) ‘Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials’.

Truveta (2024) ‘Monitoring GLP-1 RA prescription trends: March 2024’, 28 May.

U.S. Food and Drug Administration (2024) ‘Is it a cosmetic, a drug, or both? (Or is it soap?)’, 11 September.

Health Policy Partnership (2025) ‘Are weight-loss treatments contributing to health inequalities?’, 7 March.

RealSelf (2025) ‘2025 year-end Real Talk report’, 19 November.

Looking for something else?